SphingoTec Introduces PenKid at AKI & CRRT Course in Vicenza

SphingoTec GmbH, in collaboration with Boditech Med Inc., presented the kidney function biomarker Proenkephalin A 119-159 (penKid) at the 42nd AKI & CRRT Course in Vicenza, highlighting its integration with the AFIAS platform. PenKid addresses the diagnostic gaps in acute kidney injury (AKI) by providing real-time kidney function assessment.

The current standard of care for AKI diagnosis relies on serum creatinine and urine output, both of which are lagging indicators. PenKid, however, offers an improved approach by enabling real-time kidney function assessment, unaffected by inflammation.

During the scientific session, Prof. Lui Forni emphasized penKid's potential as an alternative to serum creatinine for critical care settings. A meta-analysis of data from 11 studies involving nearly 4,000 patients supports penKid's clinical performance and its role in identifying high-risk AKI patients.

PenKid could enhance patient care by enabling more intensive surveillance and early prevention efforts, possibly leading to improved outcomes in AKI management. The AFIAS penKid® test is set for market development and rollout in Europe.